var data={"title":"Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Immune globulin (Intravenous, subcutaneous, and intramsucular): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/320543?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-patient-drug-information\" class=\"drug drug_patient\">see &quot;Immune globulin (Intravenous, subcutaneous, and intramsucular): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Immune globulin (Intravenous, subcutaneous, and intramsucular): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513229\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thrombosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Thrombosis may occur with immune globulin products. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal dysfunction and acute renal failure (excluding Hizentra, HyQvia, and Gammastan):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products. Patients predisposed to renal dysfunction include those with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. (<b>Note: </b>The following products do not contain sucrose: Bivigam, Flebogamma  DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam 5%, Octagam 10%, and Privigen.) For patients at risk of renal dysfunction or acute renal failure, administer immune globulin IV products at the minimum concentration dose and infusion rate practicable. Ensure adequate hydration in patients before administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513233\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bivigam;</li>\n      <li>Carimune NF;</li>\n      <li>Cuvitru;</li>\n      <li>Flebogamma DIF;</li>\n      <li>GamaSTAN S/D;</li>\n      <li>Gammagard;</li>\n      <li>Gammagard S/D Less IgA;</li>\n      <li>Gammagard S/D [DSC];</li>\n      <li>Gammaked;</li>\n      <li>Gammaplex;</li>\n      <li>Gamunex-C;</li>\n      <li>Hizentra;</li>\n      <li>Hyqvia;</li>\n      <li>Octagam;</li>\n      <li>Privigen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513234\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cuvitru;</li>\n      <li>Gamastan S/D;</li>\n      <li>Gammagard Liquid;</li>\n      <li>Gammagard S/D;</li>\n      <li>Gamunex;</li>\n      <li>Hizentra;</li>\n      <li>IGIVnex;</li>\n      <li>Octagam 10%;</li>\n      <li>Panzyga;</li>\n      <li>Privigen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513238\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Blood Product Derivative;</li>\n      <li>\n        Immune Globulin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513277\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Some clinicians may administer IGIV formulations FDA approved only for intravenous administration as a subcutaneous infusion based on clinical judgment and patient tolerability.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>B-cell chronic lymphocytic leukemia (CLL) with hypogammaglobulinemia, prevention of bacterial infections (Gammagard S/D):</b> IV: 400 mg/kg every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic inflammatory demyelinating polyneuropathy (CIDP):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gammaked, Gamunex-C:</b> Loading dose: 2,000 mg/kg (in divided doses over 2 to 4 consecutive days); Maintenance: 1,000 mg/kg administered over 1 day every 3 weeks. Alternatively, administer 500 mg/kg/day for 2 consecutive days every 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Privigen:</b> Loading dose: 2,000 mg/kg (in divided doses over 2 to 5 consecutive days); Maintenance: 1,000 mg/kg administered in a single infusion over 1 day or divided into 2 doses over 2 consecutive days, every 3 weeks. <b>Note:</b> Maintenance therapy beyond 6 months has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis A (GamaSTAN S/D):</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Preexposure prophylaxis upon travel into endemic areas (hepatitis A vaccine preferred) (CDC 2017):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.1 <b>mL</b>/kg for anticipated risk of exposure &lt;1 month</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.2 <b>mL</b>/kg for anticipated risk of exposure 1 to 2 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Repeat dose of 0.2 <b>mL</b>/kg every 2 months for anticipated risk of exposure &ge;2 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Postexposure prophylaxis:</i> 0.1 <b>mL</b>/kg given within 14 days of exposure and/or prior to manifestation of disease; not needed if at least 1 dose of hepatitis A vaccine was given at &ge;1 month before exposure (CDC 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia (ITP):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Carimune NF: IV: Initial: 400 mg/kg/day for 2 to 5 consecutive days (6% solution recommended); Maintenance: 400 mg/kg (no more frequent than daily) as needed to maintain platelet count &ge;30,000/mm<sup>3</sup> and/or to control significant bleeding; may increase dose if needed (range: 800 to 1,000 mg/kg).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flebogamma DIF 10%: IV: 1,000 mg/kg once daily for 2 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammagard S/D: IV: 1,000 mg/kg; up to 3 total doses may be given on alternate days based on patient response and/or platelet count.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaked, Gamunex-C: IV: 1,000 mg/kg/day for 2 consecutive days (second dose may be withheld if adequate platelet response in 24 hours) <b>or</b> 400 mg/kg once daily for 5 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaplex, Octagam 10%, Privigen: IV: 1,000 mg/kg/day for 2 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Panzyga [Canadian product]: IV: 1,000 mg/kg/day for 2 consecutive days; may repeat treatment in patients who relapse</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>American College of Obstetricians and Gynecologists Guidelines</i>: IV: Initial: 1,000 mg/kg as a one-time dose for pregnant women with ITP refractory to corticosteroids, when significant side effects occur with corticosteroids, or a more rapid platelet increase is necessary; may repeat if necessary (ACOG 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>American Society of Hematology Guidelines:</i> Newly diagnosed ITP with platelets &lt;30,000/mm<sup>3</sup>: First line treatment: IV: 1,000 mg/kg as a single dose, may repeat if necessary (Neunert 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Measles:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GamaSTAN S/D: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompetent: 0.25 <b>mL</b>/kg given within 6 days of exposure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompromised children: 0.5 <b>mL</b>/kg (maximum dose: 15 <b>mL</b>) immediately following exposure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postexposure prophylaxis, any nonimmune person (off-label population): Patients &le;30 kg: 0.5 <b>mL</b>/kg (maximum dose: 15 <b>mL</b>) within 6 days of exposure. If patient &gt;30 kg, patient will have lower titers than what is recommended due to the maximum volume that can be administered (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaked, Gamunex-C, Octagam 5%: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preexposure prophylaxis in patients with primary humoral immunodeficiency (<b>ONLY</b> if routine dose is &lt;400 mg/kg): &ge;400 mg/kg immediately before expected exposure followed by resumption of prior dosing in 3 to 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postexposure prophylaxis in patients with primary humoral immunodeficiency: 400 mg/kg administered as soon as possible after exposure followed by resumption of prior dosing in 3 to 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postexposure prophylaxis, any nonimmune person (off-label population): 400 mg/kg within 6 days of exposure (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hizentra: SubQ infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preexposure prophylaxis in patients with primary humoral immunodeficiency at risk of measles exposure (eg, during an outbreak; travel to endemic area):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients receiving weekly or more frequent dosing:</i> Ensure total weekly dose of &ge;200 mg/kg for 2 consecutive weeks followed by resumption of prior dosing schedule</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients receiving biweekly dosing:</i> Administer &ge;400 mg/kg once followed by resumption of prior dosing schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Postexposure prophylaxis in patients with primary humoral immunodeficiency regardless of prior dosing schedule (daily, weekly, or biweekly): 400 mg/kg administered as soon as possible after exposure followed by resumption of prior dosing schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ACIP recommendations:</i> The Advisory Committee on Immunization Practices (ACIP) recommends postexposure prophylaxis with immune globulin (IG) to any nonimmune person exposed to measles. The following patient groups are at risk for severe measles complications and should receive IG therapy: Infants &lt;12 months of age, pregnant women without evidence of immunity; severely compromised persons (eg, persons with severe primary immunodeficiency; some bone marrow transplant patients; some ALL patients; and some patients with AIDS or HIV infection [refer to guidelines for additional details]). IGIM is recommended for infants &lt;12 months of age. IGIV is recommended for pregnant women and immunocompromised persons. Although prophylaxis may be given to any nonimmune person, priority should be given to those at greatest risk for measles complications and also to persons exposed in settings with intense, prolonged, close contact (eg, households, daycare centers, classrooms). Following IG administration, any nonimmune person should then receive the measles mumps and rubella (MMR) vaccine if the person is &ge;12 months of age at the time of vaccine administration and the vaccine is not otherwise contraindicated. MMR should not be given until 6 months following IGIM or 8 months following IGIV administration. If a person is already receiving IGIV therapy, a dose of 400 mg/kg IV within 3 weeks prior to exposure (or 200 mg/kg SubQ for 2 consecutive weeks prior to exposure if previously on SubQ therapy) should be sufficient to prevent measles infection. IG therapy is not indicated for any person who already received one dose of a measles-containing vaccine at &ge;12 months of age unless they are severely immunocompromised (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multifocal motor neuropathy (MMN) (Gammagard Liquid): </b>IV: 500 to 2400 mg/kg/<b>month</b> based upon response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary humoral immunodeficiency disorders:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV infusion dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bivigam, Gammaplex: IV: 300 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Carimune NF: IV: 400 to 800 mg/kg every 3 to 4 weeks. <b>Note:</b> In previously untreated agammaglobulinemic or hypogammaglobulinemic patients use a 3% solution; may administer subsequent infusions with a higher concentration if patient tolerates lower concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flebogamma DIF 5%, Flebogamma DIF 10%, Gammagard Liquid, Gammagard S/D, Gammaked, Gamunex-C, Octagam 5%: IV: 300 to 600 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Privigen, Panzyga [Canadian product]: IV: 200 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Switching to weekly subcutaneous infusion dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammagard Liquid, Gammaked, Gamunex-C: SubQ infusion: Begin 1 week after last IV dose. Use the following equation to calculate initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial weekly dose (grams) = [1.37 x IGIV dose (grams)] divided by [IV dose interval (weeks)]</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hizentra: SubQ infusion: For weekly or frequent (up to daily) dosing, begin 1 week after last IV infusion or SubQ infusion. For biweekly (every 2 week) dosing, begin 1 or 2 weeks after last IV infusion or 1 week after the last SubQ weekly infusion. <b>Note:</b> Patient should have received an IV immune globulin routinely for at least 3 months before switching to SubQ. Use the following equation to calculate initial weekly dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial weekly dose (grams) = [Previous IGIV dose (grams)] divided by [IV dose interval (eg, 3 or 4 weeks)] then multiply by 1.37. For patients switching to Hizentra from a different SubQ formulation, the previous weekly SubQ dose should be used initially. To convert the dose (in grams) to mL, multiply the calculated dose (in g) by 5.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Provided the total weekly dose is maintained, any dosing interval from daily up to biweekly (every 2 weeks) may be used. For patients switching to Hizentra from a different SubQ formulation, the previous weekly SubQ dose should be used initially. Use the following calculations to calculate frequent or biweekly dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Biweekly dosing (grams) = multiply the calculated or previous weekly dose by 2.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequent (2 to 7 times per week) dosing (grams) = divide the calculated or previous weekly dose by the desired number of times per week (eg, for 3 times per week dosing, divide weekly dose by 3)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>SubQ infusion dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cuvitru: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients switching from another IG SubQ product:</i> SubQ infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Weekly dosing (grams):</i> Weekly dose is the same as the prior immune globulin subcutaneous weekly dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Biweekly dosing (grams): </i>Multiply the calculated weekly dose by 2</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Frequent (2 to 7 times per week) dosing (grams):</i> Divide the calculated weekly dose by the desired number of administration times per week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients switching from IGIV therapy or Hyqvia:</i> SubQ infusion: Begin treatment one week after patient's last immune globulin IV or Hyqvia infusion</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Initial weekly dosing (grams):</i> Divide the previous immune globulin IV or Hyqvia dose (grams) by the number of weeks between IV doses, then multiply this dose by 1.3 (dose adjustment factor)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Biweekly dosing (grams): Multiply the calculated weekly dose by 2 </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Frequent (2 to 7 times per week) dosing (grams):</i> Divide the calculated weekly dose by the desired number of times per week</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HyQvia: SubQ: See manufacturer's labeling for initial ramp-up schedule (initiating treatment with a full monthly dose has not been evaluated); dose adjusted based on monitored trough serum IgG concentrations and clinical response after initial ramp-up. <b>Note:</b> For patients previously on another IgG treatment, administer the first dose ~1 week after the last infusion of previous treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients naive to IgG therapy or switching from IG SubQ therapy:</i> SubQ infusion: 300 to 600 mg/kg every 3 to 4 weeks, after the initial dose ramp-up</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients switching from IGIV therapy:</i> SubQ infusion: Administer the same dose and frequency as the previous IGIV therapy after the initial dose ramp-up. For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rubella (GamaSTAN S/D):</b> IM: Postexposure prophylaxis during pregnancy: 0.55 <b>mL</b>/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary immunodeficiency: </b>Panzyga [Canadian product]: IV: 200 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella (GamaSTAN S/D):</b> IM: Prophylaxis: 0.6 to 1.2 <b>mL</b>/kg (varicella zoster immune globulin preferred) within 72 hours of exposure (Gershon 1978). <b>Note:</b> For patients at risk of thrombosis, administer at the lower end of the recommended dosage range.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>\n          <span style=\"text-decoration: underline\">Off-label uses:</span></i></b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acquired hypogammaglobulinemia secondary to malignancy (off-label use):</b> 400 mg/kg/dose every 3 weeks; reevaluate every 4 to 6 months (Anderson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antibody-mediated rejection in cardiac transplantation, treatment (off-label use):</b> Dose/frequency/duration of treatment varies greatly: 100 to 2,000 mg/kg (dose may be divided into 2 or 4 doses) 1 to 3 times per week, often given after each plasmapheresis; may be re-dosed monthly, if re-dose necessary and based on response (AHA [Colvin 2015]; ISHLT [Costanzo 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatomyositis/polymyositis (refractory) (use in combination with other agents in patients with dermatomyositis) (off-label use):</b> 2,000 mg/kg per treatment course administered in divided doses over 2 to 5 consecutive days (eg, 400 mg/kg/day for 5 days); maximum (per treatment course): 2,000 mg/kg (Feasby 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Guillain-Barr&eacute; syndrome (off-label use):</b> A total dose of 2 g/kg per treatment course, given in divided doses over 2 to 5 consecutive days (eg, 400 mg/kg/day for 5 days) (Feasby 2007; Hughes 2014). European Federation of Neurological Societies (EFNS) guidelines recommend the 5-day treatment regimen (Elovaara 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic cell transplantation (HCT) with hypogammaglobulinemia (IgG &lt;400 mg/dL), prevention of bacterial infection (off-label use):</b> <b>Note:</b> Increase dose or frequency to maintain IgG concentration &gt;400 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;100 days post-HCT: 500 mg/kg/dose once weekly (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;100 days post-HCT: 500 mg/kg/dose every 3 to 4 weeks (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-associated thrombocytopenia (off-label use):</b> 1,000 mg/kg/day for 2 days (Anderson 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lambert-Eaton myasthenic syndrome (LEMS) (off-label use):</b> 1,000 mg/kg/day for 2 days (Bain 1996; Patwa 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis (acute exacerbation) (off-label use):</b> Adjunctive therapy: 2 g/kg per treatment course, administered in divided doses over 2 to 5 consecutive days (eg, 400 mg/kg/day for 5 days) (Barth 2011; Feasby 2007; Zinman 2007). <b>Note:</b> A single dose of 1 g/kg may have similar efficacy to 1 g/kg given on 2 consecutive days (Gajdos 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Relapsing-remitting multiple sclerosis (off-label use):</b> 1,000 mg/kg per month, with or without an induction of 400 mg/kg/day for 5 days (Feasby 2007). Optimal dosing has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513276\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Immune globulin (Intravenous, subcutaneous, and intramsucular): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> HyQvia and Octagam 10% are <b>not</b> FDA-approved for use in children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Kawasaki disease:</b> IV: 2,000 mg/kg as a single dose over 10 to 12 hours; usually given within 10 days of disease onset; however, may be given &gt;10 days from onset in patients with delayed diagnosis or with persistent symptoms of systemic inflammation with persistent fever and/or coronary artery aneurysms; must be used in combination with aspirin; if signs and symptoms persist &ge;36 hours after completion of the infusion, retreatment with a second 2,000 mg/kg infusion may be considered with or without corticosteroids. <b>Note: </b>Corticosteroids may be added for primary treatment in patients identified as high risk for development of coronary artery aneurysms (AHA [McCrindle 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis A:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Immune thrombocytopenia (ITP):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Carimune NF: IV: Initial: 400 mg/kg/day for 2 to 5 consecutive days (6% solution recommended); Maintenance: 400 mg/kg (no more frequent than daily) as needed to maintain platelet count &ge;30,000/mm<sup>3</sup> and/or to control significant bleeding; may increase dose if needed (range: 800 to 1,000 mg/kg). For acute ITP, may discontinue after day 2 if platelet response is adequate (30,000 to 50,000/mm<sup>3</sup>) after the first 2 doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flebogamma DIF 10%: Children &ge;2 years of age and Adolescents: IV: 1,000 mg/kg once daily for 2 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gammaked, Gamunex-C: IV: 1,000 mg/kg/day for 2 consecutive days (second dose may be withheld if adequate platelet response in 24 hours) <b>or</b> 400 mg/kg once daily for 5 consecutive days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Privigen: Adolescents &ge;15 years of age: IV: 1,000 mg/kg/day for 2 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Society of Hematology Guidelines:</i> Newly diagnosed ITP: Initial pharmacologic management: Children and Adolescents: IV: 800 to 1,000 mg/kg as a single dose (Neunert 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Measles:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary humoral immunodeficiency disorders: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>IV infusion dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Bivigam: IV: Children &ge;6 years of age and Adolescents: 300 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Carimune NF: IV: Children and Adolescents: 400 to 800 mg/kg every 3 to 4 weeks. <b>Note:</b> In previously untreated agammaglobulinemic or hypogammaglobulinemic patients use a 3% solution; may administer subsequent infusions with a higher concentration if patient tolerates lower concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Flebogamma DIF 5%: IV: Children &ge;2 years of age and Adolescents: 300 to 600 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gammagard Liquid, Gammagard S/D: IV: Children &ge;2 years of age and Adolescents: 300 to 600 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gammaked, Gamunex-C: IV: Children &ge;2 years of age and Adolescents: 300 to 600 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gammaplex: IV: Children &ge;2 years of age and Adolescents: 300 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Octagam 5%: IV: Children and Adolescents: 300 to 600 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Panzyga [Canadian product]: IV: Children &ge;2 years of age and Adolescents: 200 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Privigen: IV: Children &ge;3 years of age and Adolescents: 200 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Switching to weekly subcutaneous infusion dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gammagard Liquid, Gammaked, Gamunex-C: Children &ge;2 years of age and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">SubQ infusion: Begin 1 week after last IV dose. Use the following equation to calculate initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Initial weekly dose (grams) = [1.37 x IGIV dose (grams)] divided by [IV dose interval (weeks)]</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hizentra: SubQ infusion: Children &ge;2 years of age and Adolescents: For weekly or frequent (up to daily) dosing, begin 1 week after last IV infusion or SubQ infusion. For biweekly (every 2 week) dosing, begin 1 or 2 weeks after last IV infusion or 1 week after the last SubQ weekly infusion. <b>Note:</b> Patient should have received an IV immune globulin routinely for at least 3 months before switching to SubQ. Use the following equation to calculate initial weekly dose:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial weekly dose (grams) = [Previous IGIV dose (grams)] divided by [IV dose interval (eg, 3 or 4 weeks)] then multiply by 1.37. If switching from a different SubQ formulation to Hizentra, maintain previous weekly SubQ dose initially. To convert the dose (in grams) to mL, multiply the calculated dose (in grams) by 5.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> Provided the total weekly dose is maintained, any dosing interval from daily up to biweekly (every 2 weeks) may be used. Use the following calculations to calculate frequent or biweekly dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Biweekly dosing (grams) = multiply the calculated or previous weekly dose by 2.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Frequent (2 to 7 times per week) dosing (grams) = divide the calculated or previous weekly dose by the desired number of times per week (eg, for 3 times per week dosing, divide weekly dose by 3).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>Note:</b> For subsequent dose adjustments, refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>SubQ infusion dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cuvitru: SubQ infusion: Children &ge;2 years of age and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Secondary immunodeficiency: </b>Panzyga [Canadian product]: IV: Children &ge;2 years of age and Adolescents: 200 to 800 mg/kg every 3 to 4 weeks; dose adjusted based on monitored trough serum IgG concentrations and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Varicella:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatomyositis/polymyositis (refractory) (use in combination with other agents in patients with dermatomyositis) (off-label use):</b> IV: 2,000 mg/kg per treatment course administered in divided doses over 2 consecutive days (eg, 1,000 mg/kg/day for 2 days); maximum (per treatment course): 2,000 mg/kg (Feasby 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Guillain-Barr&eacute; syndrome (off-label use):</b> Children and Adolescents: IV: 1,000 mg/kg/day for 2 days (Feasby 2007; Korinthenberg 2005) <b>or</b> 400 mg/kg/day for 5 days (El-Bayoumi 2011; Korinthenberg 2005).Two-day regimens have been associated with a higher incidence of early relapse (Korinthenberg 2005). American Academy of Neurology guidelines state optimal dosing has not been established (Patwa 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic cell transplantation (HCT) with hypogammaglobulinemia (IgG &lt;400 mg/dL), prevention of bacterial infection (off-label use) (Tomblyn 2009):</b> IV: <b>Note</b>: Increase dose or frequency to maintain IgG concentration &gt;400 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;100 days post-HCT:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children (Allogeneic HCT recipients): IV: 400 mg/kg/dose once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 500 mg/kg/dose once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;100 days post-HCT: Infants, Children, and Adolescents: IV: 500 mg/kg/dose every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV infection [prophylaxis of bacterial infection in patients with hypogammaglobulinemia (IgG &lt;400 mg/dL)] (off-label use): </b>Infants and Children: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary prophylaxis for serious bacterial infections: 400 mg/kg/dose every 2 to 4 weeks (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Secondary prophylaxis for invasive bacterial infections: Should only be used if subsequent infections are frequent severe infections (&gt;2 infections during a 1-year period): 400 mg/kg/dose every 2 to 4 weeks (DHHS [pediatric] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myasthenia gravis (acute exacerbation) (off-label use):</b> Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513278\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution; administer the minimum dose and infusion rate practicable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513279\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Use with caution due to risk of immune globulin-induced renal dysfunction; the rate of infusion and concentration of solution should be minimized. Discontinue if renal function deteriorates during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ infusion: There are no dosage adjustments provided in the manufacturer's labeling; consider lower, more frequent dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15897621\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">IM, IV, SubQ infusion: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20330560\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Some clinicians dose IGIV on ideal body weight or an adjusted ideal body weight in morbidly obese patients (Siegel 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513299\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injectable, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GamaSTAN S/D: 15% to 18% [150 to 180 mg/mL] (2 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hyqvia: 2.5 g/25 mL, 5 g/50 mL, 10 g/100 mL, 20 g/200 mL, 30 g/300 mL [contains albumin human, edetate disodium dihydrate, mouse (murine) and/or hamster protein]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammagard: 1 g/10 mL (10 mL); 2.5 g/25 mL (25 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 30 g/300 mL (300 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammaked: 1 g/10 mL (10 mL); 2.5 g/25 mL (25 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gamunex-C: 1 g/10 mL (10 mL); 2.5 g/25 mL (25 mL); 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 40 g/400 mL (400 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bivigam: 5 g/50 mL (50 mL); 10 g/100 mL (100 mL) [sugar free; contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flebogamma DIF: 0.5 g/10 mL (10 mL); 5 g/50 mL (50 mL); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 20 g/400 mL (400 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammaplex: 5 g/50 mL (50 mL); 5 g/100 mL (100 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammaplex: 10 g/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammaplex: 20 g/200 mL (200 mL); 20 g/400 mL (400 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL [DSC]) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Octagam: 1 g/20 mL (20 mL); 2 g/20 mL (20 mL); 5 g/50 mL (50 mL); 5 g/100 mL (100 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 25 g/500 mL (500 mL); 10 g/200 mL (200 mL); 2.5 g/50 mL (50 mL) [sucrose free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Privigen: 5 g/50 mL (50 mL); 10 g/100 mL (100 mL); 20 g/200 mL (200 mL); 40 g/400 mL (400 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cuvitru: 1 g/5 mL (5 mL); 2 g/10 mL (10 mL); 4 g/20 mL (20 mL); 8 g/40 mL (40 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hizentra: 1 g/5 mL (5 mL); 2 g/10 mL (10 mL); 4 g/20 mL (20 mL); 10 g/50 mL (50 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carimune NF: 3 g (1 ea [DSC]); 6 g (1 ea); 12 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammagard S/D: 5 g (1 ea [DSC]); 10 g (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gammagard S/D Less IgA: 5 g (1 ea); 10 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513236\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116456\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carimune NF may contain a significant amount of sodium and also contains sucrose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gammagard S/D may contain a significant amount of sodium and also contains glucose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Octagam contains maltose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyqvia Kit is supplied with a Hyaluronidase (Human Recombinant) component intended for injection prior to Immune Globulin administration to improve dispersion and absorption of the Immune Globulin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49444101\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Intravenous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Panzyga: 1 g/10 mL (10 mL), 2.5 g/25 mL (25 mL), 5 g/50 mL (50 mL), 10 g/100 mL (100 mL), 20 g/200 mL (200 mL), 30 g/300 mL (30 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513282\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> If plasmapheresis employed for treatment of condition, administer immune globulin <b>after</b> completion of plasmapheresis session.</p>\n    <p style=\"text-indent:0em;\">IM: Administer IM in the anterolateral aspects of the upper thigh or deltoid muscle of the upper arm. Avoid gluteal region due to risk of injury to sciatic nerve. Divide doses &gt;10 mL and inject in multiple sites.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GamaSTAN S/D is for IM administration only.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">IV infusion: Infuse over 2 to 24 hours; administer in separate infusion line from other medications; if using primary line, flush with NS or D5W (product specific; consult product prescribing information) prior to administration. Decrease dose, rate and/or concentration of infusion in patients who may be at risk of renal failure. Decreasing the rate or stopping the infusion may help relieve some adverse effects (flushing, changes in pulse rate, changes in blood pressure). Epinephrine should be available during administration. For initial treatment or in the elderly, a lower concentration and/or a slower rate of infusion should be used. Initial rate of administration and titration is specific to each IGIV product. Refrigerated product should be warmed to room temperature prior to infusion. Some products require filtration; refer to individual product labeling. Antecubital veins should be used, especially with concentrations &ge;10% to prevent injection site discomfort.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bivigam 10%: Primary humoral immunodeficiency: Initial (first 10 minutes): 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase every 20 minutes (if tolerated) by 0.8 mg/kg/minute (0.48 <b>mL</b>/kg/<b>hour)</b> up to 6 mg/kg/minute (3.6 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Carimune NF: Refer to product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flebogamma DIF 5%: Primary humoral immunodeficiency: Initial: 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase slowly (if tolerated) up to 5 mg/kg/minute (6 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flebogamma DIF 10%: Primary humoral immunodeficiency or immune thrombocytopenia: Initial: 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase slowly (if tolerated) up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammagard Liquid 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Multifocal motor neuropathy (MMN): Initial: 0.8 mg/kg/minute (0.5 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) up to 9 mg/kg/minute (5.4 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary humoral immunodeficiency: Initial (first 30 minutes): 0.8 mg/kg/minute (0.5 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase every 30 minutes (if tolerated) up to: 8 mg/kg/minute (5 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammagard S/D: 5% solution: Initial: 0.5 <b>mL</b>/kg/<b>hour</b>; may increase (if tolerated) to a maximum rate of 4 <b>mL</b>/kg/<b>hour</b>. If 5% solution is tolerated at maximum rate, may administer 10% solution with an initial rate of 0.5 <b>mL</b>/kg/<b>hour</b>; may increase (if tolerated) to a maximum rate of 8 <b>mL/</b>kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaked 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CIDP: Initial (first 30 minutes): 2 mg/kg/minute (1.2 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) to a maximum of 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary humoral immunodeficiency or ITP: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) to a maximum of 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaplex 5%: Primary humoral immunodeficiency or ITP: Initial (first 15 minutes): 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase every 15 minutes (if tolerated) up to 4 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gamunex-C 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CIDP: Initial (first 30 minutes): 2 mg/kg/minute (1.2 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) to a maximum of 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary humoral immunodeficiency or ITP: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) to a maximum of 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Octagam 5%: Primary humoral immunodeficiency: Initial (first 30 minutes): 0.5 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Double infusion rate (if tolerated) every 30 minutes up to a maximum rate of &lt;3.33 mg/kg/minute (4.2 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Octagam 10%: ITP: Initial (first 30 minutes):1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: Double infusion rate (if tolerated) every 30 minutes up to a maximum rate of 12 mg/kg/minute (7.2 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Panzyga [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ITP: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: May increase gradually (if tolerated) every 15 to 30 minutes up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Primary/secondary humoral immunodeficiency: Initial (first 30 minutes): 1 mg/kg/minute (0.6 <b>mL</b>/kg/<b>hour</b>); Maintenance: May increase gradually (if tolerated) every 15 to 30 minutes up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>) in treatment-naive patients or up to 12 to 14 mg/kg/minute (7.2 to 8.4 <b>mL</b>/kg/<b>hour</b>) in treatment-experienced patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Privigen 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ITP: Initial: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) up to 4 mg/kg/minute (2.4 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CIDP/Primary humoral immunodeficiency: Initial: 0.5 mg/kg/minute (0.3 <b>mL</b>/kg/<b>hour</b>); Maintenance: Increase gradually (if tolerated) up to 8 mg/kg/minute (4.8 <b>mL</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">SubQ infusion: Initial dose should be administered in a healthcare setting capable of providing monitoring and treatment in the event of hypersensitivity. Using aseptic technique, follow the infusion device manufacturer's instructions for filling the reservoir and preparing the pump. Remove air from administration set and needle by priming. For products excluding HyQvia, appropriate injection sites include the abdomen, thigh, upper arm, lower back, and/or lateral hip; dose may be infused into multiple sites (spaced &ge;2 inches apart) simultaneously. HyQvia may be injected into the middle to upper abdomen or thigh (avoid bony prominences, or areas that are scarred, inflamed, or infected). If two sites are used simultaneously for HyQvia, the two infusion sites should be on opposite sides of the body. After the sites are clean and dry, insert subcutaneous needle and prime administration set. Attach sterile needle to administration set, gently pull back on the syringe to assure a blood vessel has not been inadvertently accessed (do not use needle and tubing if blood present). Repeat for each injection site; deliver the dose following instructions for the infusion device. Rotate the site(s) between successive infusions. Treatment may be transitioned to the home/home care setting in the absence of adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cuvitru:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites: &le;4 simultaneous injection sites (spaced 4 inches apart or more).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion rate: 10 to 20 mL/hour per injection site (first 2 infusions); may be increased to 60 mL/hour per injection site (as tolerated) for subsequent infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion volume:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients &lt;40 kg: 20 mL per injection site (first 2 infusions); may increase to 60 mL per site for subsequent infusions</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients &ge;40 kg: 60 mL per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammagard Liquid:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites: &le;8 simultaneous injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial infusion rate:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;40 kg: 15 mL/hour per injection site (maximum volume: 20 mL per injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;40 kg: 20 mL/hour per injection site (maximum volume: 30 mL per injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance infusion rate:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;40 kg: 15 to 20 mL/hour per injection site (maximum volume: 20 mL per injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;40 kg: 20 to 30 mL/hour per injection site (maximum volume: 30 mL per injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gammaked, Gamunex-C:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites: &le;8 (adults) or &le;6 (children) simultaneous injection sites (spaced &ge;2 inches apart)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recommended infusion rate:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: 20 mL/hour per infusion site</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents (&lt;25 kg): 10 mL/hour per infusion site</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents (&ge;25 kg): Initial: 15 mL/hour per infusion site; may increase up to 20 mL/hour per infusion site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hizentra:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites: &le;4 simultaneous injection sites or &le;12 sites consecutively per infusion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion rate: First infusion: 15 mL/hour per injection site; subsequent infusions: 25 mL/hour per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum infusion volume: First 4 infusions: 15 mL per injection site; subsequent infusions: 20 mL per injection site (maximum: 25 mL per site as tolerated)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HyQvia: Infuse the two components of HyQvia (immune globulin and hyaluronidase) sequentially, beginning with hyaluronidase; do not use either component alone. Infusion pump capable of infusing rates up to 300 mL/hour/site is required; must also have the ability to titrate the flow rate. Use a 24 gauge subcutaneous needle set labeled for high flow rates. Infusion site leakage can occur; consider using longer needles (14 mm or 12 mm) and/or more than one infusion site. Initiate the infusion of the full dose of the immune globulin through the same subcutaneous needle set within ~10 minutes of hyaluronidase infusion. For each full or partial vial of immune globulin used, administer the entire contents of the hyaluronidase vial. A second site can be used based on tolerability and total volume; if a second site is used, administer half of total volume of the hyaluronidase in each site. Flush the infusion line with NS or D5W if required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Injection sites:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Volume per site:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;40 kg: &le;300 mL per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;40 kg: &le;600 mL per injection site</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infusion rate:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hyaluronidase: ~1 to 2 mL/minute, or as tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immune globulin:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">First 2 infusions:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;40 kg: 5 mL/hour for 5 to 15 minutes; 10 mL/hour for 5 to 15 minutes; 20 mL/hour for 5 to 15 minutes; 40 mL/hour for 5 to 15 minutes; then 80 mL/hour for remainder of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;40 kg: 10 mL/hour for 5 to 15 minutes; 30 mL/hour for 5 to 15 minutes; 60 mL/hour for 5 to 15 minutes; 120 mL/hour for 5 to 15 minutes; then 240 mL/hour for remainder of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Next 2 or 3 infusions:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&lt;40 kg: 10 mL/hour for 5 to 15 minutes; 20 mL/hour for 5 to 15 minutes; 40 mL/hour for 5 to 15 minutes; 80 mL/hour for 5 to 15 minutes; then 160 mL/hour for remainder of infusion</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;40 kg: 10 mL/hour for 5 to 15 minutes; 30 mL/hour for 5 to 15 minutes; 120 mL/hour for 5 to 15 minutes; 240 mL/hour for 5 to 15 minutes; then 300 mL/hour for remainder of infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513241\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic inflammatory demyelinating polyneuropathy:</b> Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) (Gammaked, Gamunex-C, Privigen)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia:</b> Prevention of bacterial infection in patients with hypogammaglobulinemia and/or recurrent bacterial infections with B-cell chronic lymphocytic leukemia (CLL) (Gammagard S/D)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of acute immune thrombocytopenia (ITP) (Carimune NF, Gammagard S/D, Gammaked, Gamunex-C).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of chronic ITP (Carimune NF, Flebogamma DIF 10%, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam 10%, Panzyga [Canadian product]), Privigen)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immunodeficiency syndromes:</b> Treatment of primary humoral immunodeficiency syndromes (congenital agammaglobulinemia, severe combined immunodeficiency syndromes [SCIDS], common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome) (Bivigam, Carimune NF, Cuvitru, Flebogamma DIF, HyQvia, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Hizentra, Octagam 5%, Panzyga [Canadian product], Privigen); Treatment of secondary immunodeficiency (Panzyga [Canadian product])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Kawasaki syndrome:</b> Prevention of coronary artery aneurysms associated with Kawasaki syndrome (in combination with aspirin) (Gammagard S/D)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multifocal motor neuropathy:</b> Treatment of multifocal motor neuropathy (MMN) (Gammagard Liquid)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Passive immunity:</b> Provision of passive immunity in the following susceptible individuals (GamaSTAN S/D):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatitis A: Pre-exposure prophylaxis; postexposure: within 14 days and/or prior to manifestation of disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Measles: For use within 6 days of exposure in an unvaccinated person, who has not previously had measles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rubella: Postexposure prophylaxis to reduce the risk of infection and fetal damage in exposed pregnant women who will not consider therapeutic abortion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Varicella: For immunosuppressed patients when varicella zoster immune globulin is not available</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26122978\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acquired hypogammaglobulinemia secondary to malignancy; Antibody-mediated rejection (AMR) in cardiac transplantation (treatment); Dermatomyositis/polymyositis (refractory); Guillain-Barr&eacute; syndrome (adults); Guillain-Barr&eacute; syndrome (children/adolescents); Hematopoietic cell transplantation with hypogammaglobulinemia (prevention of bacterial infection); HIV (prophylaxis of bacterial infection in pediatric patients with hypogammaglobulinemia [IgG &lt;400 mg/dL]); HIV-associated thrombocytopenia; Lambert-Eaton myasthenic syndrome; Myasthenia gravis (acute exacerbation); Relapsing-remitting multiple sclerosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513231\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gamimune N may be confused with CytoGam</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immune globulin (intravenous) may be confused with hepatitis B immune globulin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Privigen (immune globulin) may be confused with Albuminar-25 (albumin) due to similar packaging </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513249\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects are reported as class effects rather than for specific products. Adverse effects occur with intravenous administration unless otherwise specified. Some clinical trials were extremely small and skewed the incidence upward (&quot;&le;&quot; indicates this trend).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (&le;14%; children and adolescents: 25%), tachycardia (5%; children and adolescents: 25%), decreased diastolic blood pressure (5%; children and adolescents: 21%), decreased heart rate (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2% to 75%; children and adolescents: 42%; subcutaneous: 13% to 21%), fatigue (6% to 29%; subcutaneous: 11%), chills (5% to 19%), pain (5% to 15%), rigors (7% to 13%), dizziness (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Injection site pruritus (2% to 15%), ecchymosis (&le;40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Sore throat (11% to 35%), abdominal pain (6% to &le;33%; children and adolescents: 8%), diarrhea (5% to 28%; children and adolescents: 8%), vomiting (&le;26%; children and adolescents: 8%; subcutaneous: 7%), nausea (5% to 22%; children and adolescents: 8%; subcutaneous: 7%), upper abdominal pain (&le;20%; children and adolescents: &le;15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Positive direct Coombs test (&le;47%), purpura (&le;40%), hemorrhage (29%), petechiae (21%), thrombocytopenia (15%), anemia (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (all elevations were transient and generally mild: &le;18%, children and adolescents, &gt;2.5 x ULN: &le;7%; subcutaneous: &le;3%), increased serum alkaline phosphatase (subcutaneous: &le;13%; mild and transient), hyperbilirubinemia (unconjugated: 11%; conjugated: 9%; total: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (subcutaneous: 18%; non-neutralizing antibodies to recombinant human hyaluronidase)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (injection/infusion site: &le;21%), erythema at injection site (3% to 21%), infusion site reaction (6% to 13%; subcutaneous: 75%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular and skeletal: Arthralgia (&lt;5% to 20%; subcutaneous: 6%), limb pain (intravenous/subcutaneous: 6% to 15%), muscle cramps (&le;14%), back pain (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (9% to 18%; subcutaneous: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Nephrolithiasis (&le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (6% to 54%), nasal congestion (&le;52%), rhinitis (5% to 51%), sinusitis (&le;50%), pharyngitis (5% to 41%), asthma (9% to 29%; including exacerbation), upper respiratory tract infection (8% to 25%), epistaxis (7% to 23%), bronchitis (5% to 22%), nasopharyngitis (17%), rhinorrhea (7% to 17%), sinus congestion (15%), nasal mucosa swelling (&le;13%), wheezing (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (10% to 33%; subcutaneous: 6% to 7%), accidental injury (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (&le;9%), hypertension (&le;9%), peripheral edema (8%), cardiac arrest (&le;8%; Octagam: 5%), heart murmur (7%), chest discomfort (&le;7%), flushing (6%), thrombosis (&le;2%; including vena cava)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (9%), migraine (5% to 7%), lethargy (&le;6%), fibromyalgia syndrome (exacerbation: 5%), malaise (&le;5%), vertigo (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&le;10%), cellulitis (&le;8%), urticaria (&le;8%; may be transient), hyperhidrosis (6%), eczema (&le;5%; may be transient), xeroderma (&le;5%), erythema (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Ketonuria (&le;8%; Octagam: 5%), dehydration (&le;6%), increased lactate dehydrogenase (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (6% to 9%), gastroenteritis (&le;8%), pseudomembranous colitis (&le;8%), gastritis (6%), stomach discomfort (6%), abdominal distress (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vulvovaginal candidiasis (9%), urinary tract infection (&le;9%), cystitis (&le;5%), dysuria (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hematocrit (5%), bruise (&le;4%), hematoma (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (intravenous/subcutaneous: &le;9%), decreased serum alkaline phosphatase (subcutaneous: &le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection (7% to 9%), infection (positive blood culture: &le;8%), influenza (5%), viral infection (coxsackievirus: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local swelling (at injection/infusion site: &le;8%), local inflammation (at infusion site: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&le;10%), myalgia (&le;8%), muscle spasm (7%), myasthenia (7%), neck pain (6%), joint effusion (&le;6%), joint swelling (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (9%), eye discharge (7%), eye irritation (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otitis media (7% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Exacerbation of asthma (7% to 9%), tonsil disease (children: 8%), dyspnea (7% to 8%), pharyngolaryngeal pain (5% to 8%), pneumonia (&le;8%), oropharyngeal pain (6% to 7%), post nasal drip (7%), throat irritation (7%), flu-like symptoms (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Facial flushing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Localized tenderness (intramuscular), local pain (intramuscular/subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Leg cramps</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, acute respiratory distress, agitation, allergic dermatitis, alopecia, altered blood pressure, anaphylactic shock, anaphylactoid reaction, anaphylaxis, angioedema, anorexia, anxiety, apnea, arterial thrombosis, aseptic meningitis, bradycardia, bronchospasm, bullous dermatitis, burning sensation, cerebrovascular accident, chest tightness, circulatory shock, coma, cyanosis, deep vein thrombosis, dermatitis, disseminated intravascular coagulation (intravenous, subcutaneous, intramuscular; FDA Safety Communication, November 13, 2012), edema, epidermolysis, erythema multiforme, erythematous rash, exacerbation of autoimmune pure red cell aplasia, eye pain, facial edema, hematuria, hemoglobinuria, hemolysis (may be mild), hemolytic anemia (may be delayed), hepatic insufficiency, hepatitis (non-infectious), hyperventilation, hypervolemia, hypoxemia, jaundice, laryngospasm, leukopenia, loss of consciousness, lymphadenopathy, muscle rigidity, musculoskeletal pain, myocardial infarction, osmotic nephrosis, oxygen saturation decreased, pallor, palpitations, pancytopenia, paresthesia, peripheral vascular insufficiency, pharyngeal edema, phlebitis, photophobia, proximal tubular nephropathy, pulmonary edema, pulmonary embolism, renal failure, renal insufficiency, renal tubular necrosis, respiratory distress, respiratory failure, restlessness, retinal thrombosis, seizure, skin ulceration at injection site (infusion site), Stevens-Johnson syndrome, syncope, thromboembolism, thrombophlebitis, transfusion-related acute lung injury, transient ischemic attacks, tremor, urine discoloration, vena cava thrombosis, visual impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513246\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to immune globulin or any component of the formulation; IgA deficiency (with anti-IgA antibodies and history of hypersensitivity [excluding Gammagard S/D]); hyperprolinemia (Hizentra, Privigen); isolated IgA deficiency (GamaSTAN S/D); severe thrombocytopenia or coagulation disorders where IM injections are contraindicated (GamaSTAN S/D); hypersensitivity to corn (Octagam); hereditary intolerance to fructose (excluding Flebogamma); infants/neonates for whom sucrose or fructose tolerance has not been established (Gammaplex); hypersensitivity to hyaluronidase, human albumin, or any component of the hyaluronidase formulation (HyQvia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for immune globulins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513247\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur (some severe); patients with known antibodies to IgA are at greater risk; a severe fall in blood pressure may rarely occur with anaphylactic reaction; discontinue therapy and institute immediate treatment (including epinephrine 1 mg/mL) should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with immune globulin administration; may occur with high doses (&ge;1 g/kg) and/or rapid infusion. Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after product is discontinued. Female patients or patients with a migraine history may be at higher risk for AMS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematoma: Increased risk of hematoma formation when administered subcutaneously for the treatment of ITP.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolysis: Intravenous immune globulin has been associated with antiglobulin hemolysis (acute or delayed). Cases of hemolysis-related renal impairment/failure or disseminated intravascular coagulation (DIC) have been reported. Risk factors associated with hemolysis include high doses (&ge;2 g/kg) given either as a single administration or divided over several days, underlying associated inflammatory conditions, and non-O blood type (FDA 2012). An underlying inflammatory state (eg, elevated C-reactive protein or erythrocyte sedimentation rate) may also increase the risk. Closely monitor patients for signs of hemolytic anemia, particularly in patients with pre-existing anemia and/or cardiovascular or pulmonary compromise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hereditary fructose intolerance: Immune globulin may contain sorbitol. The presence of sorbitol presents a risk to those with hereditary fructose intolerance (HFI). The incidence of HFI is estimated at 1 in 20,000 births and is usually diagnosed at the time of weaning when fructose or sucrose is introduced into the diet. Clinical symptoms include recurrent vomiting, abdominal pain, and hypoglycemia. Immune globulin must not be administered to patients with HFI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperproteinemia: Hyperproteinemia, increased serum viscosity, and hyponatremia may occur; distinguish hyponatremia from pseudohyponatremia to prevent volume depletion, a further increase in serum viscosity and a higher risk of thrombotic events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension urgency: Elevations of blood pressure (systolic &ge;180 mm Hg and/or diastolic &ge;120 mm Hg) have been observed during and/or shortly following infusion of Privigen which resolved with either observation or changes in oral anti-hypertensive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Patients should be monitored for adverse events during and after the infusion. Stop administration with signs of infusion reaction (fever, chills, nausea, vomiting, and rarely shock). Risk may be increased with initial treatment, when switching brands of immune globulin, and with treatment interruptions of &gt;8 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever in the presence of normal left ventricular function. Usually occurs within 1 to 6 hours after infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: IV administration only: Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure, osmotic nephrosis) can rarely occur and has been associated with fatalities; usually within 7 days of use (more likely with products stabilized with sucrose). Use with caution in the elderly, patients with renal disease, diabetes mellitus, overweight, hypovolemia, volume depletion, sepsis, paraproteinemia, and nephrotoxic medications due to risk of renal dysfunction.</b> In patients at risk of renal dysfunction, ensure adequate hydration prior to administration; the dose rate of infusion and concentration of solution should be minimized. Assess renal function prior to treatment and periodically thereafter. Discontinue if renal function deteriorates.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events:<b> [US Boxed Warning]: Thrombosis may occur with immune globulin products even in the absence of risk factors for thrombosis. For patients at risk of thrombosis (eg, advanced age, history of atherosclerosis, impaired cardiac output, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors), administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity such as those with cryoglobulins, fasting chylomicronemia/severe hypertriglyceridemia, or monoclonal gammopathies.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: High-dose regimens (1 g/kg for 1 to 2 days) are not recommended for individuals with fluid overload or where fluid volume may be of concern.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypovolemia: Patients should not be volume depleted prior to initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IgA deficiency: Increased risk of hypersensitivity, especially in patients with anti-IgA antibodies; use is contraindicated in patients with IgA deficiency (with antibodies against IgA and history of hypersensitivity) or isolated IgA deficiency (GamaSTAN S/D).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ITP, chronic: Consider risk versus benefit for high-dose regimen in patients with increased risk of thrombosis, hemolysis, acute kidney injury, or volume overload.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; ensure adequate hydration prior to administration; the rate of infusion and concentration of solution should be minimized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be at increased risk for renal dysfunction/failure and thromboembolic events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt Jakob disease [CJD] agent) which could transmit disease, including unknown or emerging viruses and other pathogens. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging of some products may contain natural latex/natural rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; L-proline: Hizentra and Privigen contain the stabilizer L-proline and are contraindicated in patients with hyperprolinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maltose: Some products may contain maltose, which may result in falsely elevated blood glucose readings. Maltose-containing products may be contraindicated with patients with corn allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC, 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin testing: Skin testing should not be performed with GamaSTAN S/D as local irritation can occur and be misinterpreted as a positive reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium: Some products may contain sodium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sorbitol: Some products may contain sorbitol; do not use immune globulin in patients with hereditary fructose intolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Subcutaneous administration: Some clinicians may administer intravenous immune globulin products as a subcutaneous infusion based on patient tolerability and clinical judgment. SubQ infusion should begin 1 week after the last IV dose; dose should be individualized based on clinical response and serum IgG trough concentrations. Consider premedicating with acetaminophen and diphenhydramine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sucrose: Some products may contain sucrose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Patients should be adequately hydrated prior to therapy. Do not infuse into or around an infected area due to the risk of spreading a localized infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Privigen maintenance therapy in chronic inflammatory demyelinating polyneuropathy (CIDP) has not been studied for periods longer than 6 months; after responding during an initial treatment period, not all patients require indefinite maintenance therapy in order to remain free of CDIP symptoms; individualize the duration of any treatment beyond 6 months based upon patient's response and need for continued therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccinations: Response to live vaccinations may be impaired.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299513\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513254\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16471&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the thrombogenic effect of Immune Globulin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<b> Exceptions: </b>Influenza Virus Vaccine (Live/Attenuated); Rotavirus Vaccine; Yellow Fever Vaccine; Zoster Vaccine (Live/Attenuated).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513243\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513244\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Immune globulins cross the placenta in increased amounts after 30 weeks gestation. Intravenous immune globulin has been recommended for use in fetal-neonatal alloimmune thrombocytopenia and pregnancy-associated ITP (ACOG 2016; Anderson, 2007; Neunert 2011); use is appropriate for ITP in cases refractory to corticosteroids, when side effects to corticosteroids are significant, or when a rapid increase in platelets is needed (ACOG 2016). Intravenous immune globulin is recommended to prevent measles in nonimmune women exposed during pregnancy (CDC 2013). May also be used in postexposure prophylaxis for rubella to reduce the risk of infection and fetal damage in exposed pregnant women who will not consider therapeutic abortion (per GamaSTAN S/D product labeling; use for postexposure rubella prophylaxis is not currently recommended [CDC 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>HyQvia:</i></b> Women who become pregnant during treatment are encouraged to enroll in the HyQvia Pregnancy Registry (1-866-424-6724).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20627743\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if immune globulin from these preparations is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513281\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513287\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function (prior to initial infusion and at appropriate intervals), urine output, IgG concentrations, hemoglobin and hematocrit, platelets (in patients with ITP); infusion- or injection-related adverse reactions, anaphylaxis, signs and symptoms of thrombosis, signs and symptoms of hemolysis; blood viscosity (in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; neurologic symptoms (if AMS suspected); pulmonary adverse reactions; blood pressure (prior to, during, and following infusion); clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">For patients at high risk of hemolysis (dose &ge;2 g/kg, given as a single dose or divided over several days, and non-O blood type): Hemoglobin or hematocrit prior to and 36 to 96 hours postinfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">SubQ infusion: Monitor IgG trough levels every 2 to 3 months before/after conversion from IV; subcutaneous infusions provide more constant IgG levels than usual IV immune globulin treatments.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513265\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replacement therapy for primary and secondary immunodeficiencies, and IgG antibodies against bacteria, viral, parasitic and mycoplasma antigens; interference with F<sub>c</sub> receptors on the cells of the reticuloendothelial system for autoimmune cytopenias and ITP; provides passive immunity by increasing the antibody titer and antigen-antibody reaction potential </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11513267\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: Provides immediate antibody levels</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immune thrombocytopenia: Initial response: 1 to 3 days; Peak response: 2 to 7 days (Neunert 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: IM, IV: Immune effect: 3 to 4 weeks (variable)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.05 to 0.13 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intravascular portion (primarily): Healthy subjects: 41% to 57%; Patients with congenital humoral immunodeficiencies: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IM: ~23 days; SubQ: ~59 days (HyQvia); IV: IgG (variable among patients): Healthy subjects: 14 to 24 days; Patients with congenital humoral immunodeficiencies: 26 to 40 days; hypermetabolism associated with fever and infection have coincided with a shortened half-life</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Plasma: SubQ: Cuvitru: ~4.4 days; Gammagard Liquid: 2.9 days; Hizentra: 2.9 days; HyQvia: ~5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum: IM: ~48 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322887\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Hyqvia Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g/25 mL (26.25 mL): $566.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (52.5 mL): $1,132.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (105 mL): $2,264.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (210 mL): $4,528.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 g/300 mL (315 mL): $6,793.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Bivigam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $798.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,596.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cuvitru Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/5 mL (5 mL): $205.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/10 mL (10 mL): $411.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/20 mL (20 mL): $822.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 g/40mL (40 mL): $1,645.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Flebogamma DIF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 g/10 mL (10 mL): $54.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 gm/50 mL (50 mL): $274.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g/100 mL (100 mL): $548.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $548.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,096.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/200 mL (200 mL): $1,096.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $2,192.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/400 mL (400 mL): $2,192.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gammagard Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (10 mL): $159.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g/25 mL (25 mL): $399.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $799.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,598.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,197.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 g/300 mL (300 mL): $4,796.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gammaked Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (10 mL): $152.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g/25 mL (25 mL): $380.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $760.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,520.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,041.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gammaplex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g/100 mL (100 mL): $914.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $943.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,887.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/200 mL (200 mL): $1,829.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,775.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/400 mL (400 mL): $3,658.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gamunex-C Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/10 mL (10 mL): $131.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g/25 mL (25 mL): $328.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $657.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,315.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $2,631.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 g/400 mL (400 mL): $5,261.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hizentra Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/5 mL (5 mL): $201.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/10 mL (10 mL): $403.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/20 mL (20 mL): $806.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 gm/50 mL (50 mL): $2,016.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Octagam Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/20 mL (20 mL): $166.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g/20 mL (20 mL): $332.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 gm/50 mL (50 mL): $415.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g/100 mL (100 mL): $830.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $830.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,661.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/200 mL (200 mL): $1,661.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,322.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 g/500 mL (500 mL): $4,152.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Privigen Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 gm/50 mL (50 mL): $816.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g/100 mL (100 mL): $1,632.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 g/200 mL (200 mL): $3,264.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 g/400 mL (400 mL): $6,528.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Carimune NF Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 g (1): $691.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 g (1): $1,382.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Gammagard S/D Less IgA Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g (1): $1,012.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (1): $2,024.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059490\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Allerglobuline (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Aragam (GB);</li>\n      <li>Aunativ (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Beriglobin (AE, AT, BH, CH, CY, DE, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SE, SY, YE);</li>\n      <li>Beriglobin P (AR, TW);</li>\n      <li>Beriglobina (BR, ES);</li>\n      <li>Beriglobina P (CL);</li>\n      <li>Endobulin (CZ, FI);</li>\n      <li>Flebogamma (HK, IL, MY, SG, TH);</li>\n      <li>Gamastan Immune Globulin (IL);</li>\n      <li>Gamimune (KW, QA);</li>\n      <li>Gamma 16 (IL);</li>\n      <li>Gamma I.V. (IN, PH);</li>\n      <li>Gammagard (BG, DK, ES, FR, GB, HN, IT, NL, PL, SE);</li>\n      <li>Gammagard S/D (HK, IL, SA);</li>\n      <li>Gammanorm (AE, FR, GB);</li>\n      <li>Gammaplex (GB);</li>\n      <li>Gammonativ (AE, BH, CY, DE, DK, EG, IQ, IR, JO, KW, LB, LY, NO, OM, QA, SA, SE, SY, YE);</li>\n      <li>Gamunex (AE, CY, ID, IL);</li>\n      <li>Gamunex C (SG);</li>\n      <li>Gamunex-C (HK, MY, TH);</li>\n      <li>Globuman Berna (PH);</li>\n      <li>Hizentra (AR, AT, AU, BE, BR, CH, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, JP, LB, LT, LU, NL, NO, NZ, PE, PL, PT, RO, SE, TR);</li>\n      <li>Humaglobin (VN);</li>\n      <li>Humoglob (PH);</li>\n      <li>I.V.-Globulin SN (PH);</li>\n      <li>IG Gamma (IL);</li>\n      <li>IG Vena (HK, PH);</li>\n      <li>Ig Vena NIV (ID);</li>\n      <li>Immunorel (PH);</li>\n      <li>Intragam P (AU, HK, ID);</li>\n      <li>Intraglobin (CH, DE, IT, TW);</li>\n      <li>Intraglobin F (IL);</li>\n      <li>Intratect (GB, HK, ID);</li>\n      <li>IV Globulin-S (KR);</li>\n      <li>Kiovig (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, IE, IL, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Klovig (TH);</li>\n      <li>Octagam (AT, AU, BE, BG, BH, BR, CH, CO, CZ, DE, DK, EE, FI, FR, GB, GR, HR, ID, IN, LB, LT, MT, MX, MY, NL, NO, NZ, PH, PL, RO, SA, SE, SI, SK, TH, UY, VN);</li>\n      <li>Pentaglobin (AT, DE, SG, TH, VN);</li>\n      <li>Privigen (IL);</li>\n      <li>Sandoglobulin (AE, BH, CZ, DK, EG, FI, GR, IL, KW, LB, LK, NO, NZ, PK, QA);</li>\n      <li>Sandoglobulina (CO, IT, PE);</li>\n      <li>Subcuvia (FR, GB);</li>\n      <li>Subgam (GB, IE);</li>\n      <li>Tegeline (LB);</li>\n      <li>Vena IG (LK);</li>\n      <li>Vigam (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Subcommittee on Hyperbilirubinemia, &ldquo;Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation,&rdquo; <i>Pediatrics</i>, 2004, 114(1):297-316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/15231951/pubmed\" target=\"_blank\" id=\"15231951\">15231951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists&rsquo; Committee on Practice Bulletins&mdash;Obstetrics. Practice Bulletin No. 166: Thrombocytopenia in Pregnancy. <i>Obstet Gynecol</i>. 2016;128(3):e43-e53. doi: 10.1097/AOG.0000000000001641.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/27548554/pubmed\" target=\"_blank\" id=\"27548554\">27548554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17397769\"></a>Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. <i>Transfus Med Rev</i>. 2007;21(2 suppl 1):s9-s56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/17397769/pubmed\" target=\"_blank\" id=\"17397769\">17397769</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP Commission on Therapeutics, &ldquo;ASHP Therapeutic Guidelines for Intravenous Immune Globulin,&rdquo; <i>Am J Hosp Pharm</i>, 1992, 49(3):652-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/1598949/pubmed\" target=\"_blank\" id=\"1598949\">1598949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8797464\"></a>Bain PG, Motomura M, Newsom-Davis J, et al, &ldquo;Effects of Intravenous Immunoglobulin on Muscle Weakness and Calcium-Channel Autoantibodies in the Lambert-Eaton Myasthenic Syndrome,&rdquo; <i>Neurology</i>, 1996, 47(3):678-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/8797464/pubmed\" target=\"_blank\" id=\"8797464\">8797464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. <i>Neurology</i>. 2011;76(23):2017-2023.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/21562253/pubmed\" target=\"_blank\" id=\"21562253\">21562253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blanchette VS, Luke B, Andrew M, et al, &ldquo;A Prospective Randomized Trial of High-Dose Intravenous Immune Globulin G Therapy, Oral Prednisone Therapy, and No Therapy in Childhood Acute Immune Thrombocytopenic Purpura,&rdquo; <i>J Pediatr</i>, 1993, 123(6):989-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/8229536/pubmed\" target=\"_blank\" id=\"8229536\">8229536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bivigam (immune globulin intravenous [human]) [prescribing information]. Boca Raton, FL: Biotest Pharmaceuticals Corporation; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7621634\"></a>Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. <i>Clin Lab Haematol</i>. 1995;17(1):75-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/7621634/pubmed\" target=\"_blank\" id=\"7621634\">7621634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    British Committee for Standards in Haematology General Haematology Task Force, &ldquo;Guidelines for the Investigation and Management of Idiopathic Thrombocytopenic Purpura in Adults, Children and in Pregnancy,&rdquo; <i>Br J Haematol</i>, 2003, 120(4):574-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/12588344/pubmed\" target=\"_blank\" id=\"12588344\">12588344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carimune NF (immune globulin intravenous [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; September 2013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/12588344/pubmed\" target=\"_blank\" id=\"12588344\">12588344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons - 2002 Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America,&rdquo; <i>MMWR Recomm Rep</i>, 2002, 51(RR-8):1-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/12081007/pubmed\" target=\"_blank\" id=\"12081007\">12081007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation,&rdquo; <i>MMWR Recomm Rep</i>, 2000, 49(RR-10):1-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/11718124/pubmed\" target=\"_blank\" id=\"11718124\">11718124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Hepatitis A Questions and Answers for Health Professionals. Updated October 2017. AVailable at <a href=\"https://www.cdc.gov/hepatitis/hav/havfaq.htm\" target=\"_blank\">https://www.cdc.gov/hepatitis/hav/havfaq.htm</a>. Accessed October 10, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo; <i>MMWR Recomm Rep</i>, 2006, 55(RR-7):1-23. Available at <a href=\"http://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf\" target=\"_blank\">http://www.cdc.gov/mmwr/PDF/rr/rr5507.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16708058/pubmed\" target=\"_blank\" id=\"16708058\">16708058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP),&quot; <i>MMWR Recomm Rep</i>, 2013 62(RR-04):1-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/23760231/pubmed\" target=\"_blank\" id=\"23760231\">23760231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7909099\"></a>Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. <i>Lancet</i>. 1994;343(8905):1059-1063.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/7909099/pubmed\" target=\"_blank\" id=\"7909099\">7909099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cherin P, Herson S, Wechsler B, et al, &ldquo;Efficacy of Intravenous Gammaglobulin Therapy in Chronic Refractory Polymyositis and Dermatomyositis: An Open Study With 20 Adult Patients,&rdquo; <i>Am J Med</i>, 1991, 91(2):162-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/1714235/pubmed\" target=\"_blank\" id=\"1714235\">1714235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colvin MM, Cook JL, Chang P, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(18):1608-1639.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/25838326/pubmed\" target=\"_blank\" id=\"25838326\">25838326</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costanzo MR, Dipchand A, Starling R, et al; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2010;29(8):914-956. doi: 10.1016/j.healun.2010.05.034.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/20643330/pubmed\" target=\"_blank\" id=\"20643330\">20643330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuvitru (immune globulin subcutaneous [human]) [prescribing information]. Westlake Village, CA: Baxalta US Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalakas MC, &ldquo;Intravenous Immunoglobulin In Autoimmune Neuromuscular Diseases,&rdquo; <i>JAMA</i>, 2004, 291(19):2367-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/15150209/pubmed\" target=\"_blank\" id=\"15150209\">15150209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalakas MC and Hohlfeld R, &ldquo;Polymyositis and Dermatomyositis,&rdquo; <i>Lancet</i>, 2003, 362(9388):971-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/14511932/pubmed\" target=\"_blank\" id=\"14511932\">14511932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalakas MC, Illa I, Dambrosia JM, et al, &ldquo;A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis,&rdquo; <i>N Engl J Med</i>, 1993, 329(27):1993-2000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/8247075/pubmed\" target=\"_blank\" id=\"8247075\">8247075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dattani SJ and Connelly JF, &ldquo;Oral Immunoglobulins for Gastroenteritis,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(11):1323-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/8913416/pubmed\" target=\"_blank\" id=\"8913416\">8913416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1940058\"></a>De Simone C1, Tzantzoglou S, Santini G, et al. Clinical and immunologic effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients. <i>Immunopharmacol Immunotoxicol</i>. 1991;13(3):447-458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/1940058/pubmed\" target=\"_blank\" id=\"1940058\">1940058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"DHHS.2013\"></a>DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Accessed January 12, 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eijkhout HW, van Der Meer JW, Kallenberg CG, et al, &ldquo;The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections In Patients With Primary Hypogammaglobulinemia. A Randomized, Double-Blind, Multicenter Crossover Trial,&rdquo;<i> Ann Intern Med</i>, 2001, 135(3):165-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/11487483/pubmed\" target=\"_blank\" id=\"11487483\">11487483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr&eacute; syndrome: a randomized study. <i>Crit Care</i>. 2011;15(4):R164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/21745374/pubmed\" target=\"_blank\" id=\"21745374\">21745374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elovaara I, Apostolski S, van Doorn P, et al; EFNS. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS Task Force on the use of intravenous immunoglobulin in treatment of neurological diseases. <i>Eur J Neurol</i>. 2008;15(9):893-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/18796075/pubmed\" target=\"_blank\" id=\"18796075\">18796075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. <i>Lancet</i>. 1997;349(9052):589-593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/9057729/pubmed\" target=\"_blank\" id=\"9057729\">9057729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Communication: updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products. November, 13, 2012. <a href=\"http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm?source=govdelivery%20ljb\" target=\"_blank\">http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm?source=govdelivery ljb</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17397768\"></a>Feasby T, Banwell B, Benstead T, et al, &ldquo;Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions,&rdquo; <i>Transfus Med Rev</i>, 2007, 21(2 Suppl 1):57-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/17397768/pubmed\" target=\"_blank\" id=\"17397768\">17397768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. <i>Cochrane Database Syst Rev</i>. 2013;6:CD008933. doi:10.1002/14651858.CD008933.pub2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/23744661/pubmed\" target=\"_blank\" id=\"23744661\">23744661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flebogamma 5% DIF (immune globulin intravenous [human]) [prescribing information]. Barcelona, Spain: Instituto Grifols, SA; July 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/23744661/pubmed\" target=\"_blank\" id=\"23744661\">23744661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flebogamma 5% (immune globulin) [prescribing information]. Los Angeles, CA: Grifols USA Inc; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flebogamma 10% DIF (immune globulin intravenous [human]) [prescribing information]. Barcelona, Spain: Instituto Grifols; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. <i>Arch Neurol</i>. 2005;62(11):1689-1693.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16286541/pubmed\" target=\"_blank\" id=\"16286541\">16286541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GamaSTAN S/D (immune globulin intramuscular [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics Inc; June 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16286541/pubmed\" target=\"_blank\" id=\"16286541\">16286541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammagard Liquid (immune globulin intravenous and subcutaneous [human]) [prescribing information]. Westlake Village, CA: Baxalta US Inc; June 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16286541/pubmed\" target=\"_blank\" id=\"16286541\">16286541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammagard S/D (immune globulin intravenous [human]) [prescribing information]. Westlake Village, CA: Baxalta US Inc; March 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16286541/pubmed\" target=\"_blank\" id=\"16286541\">16286541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammagard S/D (immune globulin intravenous [human]) [product monograph]. Mississauga, Ontario: Baxalta Canada Corporation; March 2, 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16286541/pubmed\" target=\"_blank\" id=\"16286541\">16286541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammaked (immune globulin intravenous and subcutaneous [human]) [prescribing information]. Fort Lee, NJ: Kedrion Biopharma, Inc; September 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16286541/pubmed\" target=\"_blank\" id=\"16286541\">16286541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gammaplex (Immune Globulin Intravenous [human]) [prescribing information]. Raleigh, NC: Bio Products Laboratory; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gamunex-C (immune globulin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gottstein R and Cooke RW, &ldquo;Systematic Review of Intravenous Immunoglobulin in Haemolytic Disease of the Newborn,&rdquo; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2003, 88(1):F6-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/12496219/pubmed\" target=\"_blank\" id=\"12496219\">12496219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2492832\"></a>Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. <i>Blood</i>. 1989;73(2):366-368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/2492832/pubmed\" target=\"_blank\" id=\"2492832\">2492832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grillo JA, Gorson, KC, Ropper AH, et al, &ldquo;Rapid Infusion of Intravenous Immune Globulin in Patients With Neuromuscular Disorders,&rdquo; <i>Neurology</i>, 2001, 57:1699-1701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/11706114/pubmed\" target=\"_blank\" id=\"11706114\">11706114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gurcan HM and Ahmed AR, &ldquo;Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders,&rdquo; <i>Ann Pharmacother</i>, 2007, 41(5):812-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/17440006/pubmed\" target=\"_blank\" id=\"17440006\">17440006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hilgartner MW and Bussel J, &ldquo;Use of Intravenous Gamma Globulin for the Treatment of Autoimmune Neutropenia of Childhood and Autoimmune Hemolytic Anemia,&rdquo; <i>Am J Med</i>, 1987, 83(4A):25-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/3118705/pubmed\" target=\"_blank\" id=\"3118705\">3118705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hizentra (immune globulin) [prescribing information]. Kankakee, IL: CSL Behring LLC; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RA, Bouche P, Cornblath DR, et al, &ldquo;European Federation of Neurological Societies/Peripheral Nerve Society Guideline on Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society,&rdquo; <i>Eur J Neurol</i>, 2006, 13(4):326-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16643309/pubmed\" target=\"_blank\" id=\"16643309\">16643309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr&eacute; syndrome. <i>Cochrane Database Syst Rev</i>. 2014;9:CD002063. doi:10.1002/14651858.CD002063.pub6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/25238327/pubmed\" target=\"_blank\" id=\"25238327\">25238327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RA, Wijdicks EF, Barohn R, et al, &ldquo;Practice Parameter: Immunotherapy for Guillain-Barr&eacute; Syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology,&rdquo; <i>Neurology</i>, 2003, 61(6):736-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/14504313/pubmed\" target=\"_blank\" id=\"14504313\">14504313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HyQvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) [prescribing information]. Westlake Village, CA: Baxalta US Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HYQVIA (immune globulin subcutaneous [human]) [prescribing information]. Westlake Village, CA: Baxter Healthcare Corporation; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2901668\"></a>Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia (CGSIGCLL). <i>N Engl J Med</i>. 1988;319(14):902-907.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/2901668/pubmed\" target=\"_blank\" id=\"2901668\">2901668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8091463\"></a>Jahnke L1, Applebaum S, Sherman LA, et al. An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia. <i>Transfusion</i>. 1994;34(9):759-764.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/8091463/pubmed\" target=\"_blank\" id=\"8091463\">8091463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Korinthenberg R, Schessl J, Kirschner J, M&ouml;nting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr&eacute; syndrome: a randomized trial. <i>Pediatrics</i>. 2005;116(1):8-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/15995024 /pubmed\" target=\"_blank\" id=\"15995024 \">15995024 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuwabara S, &ldquo;Guillain-Barr&eacute; Syndrome: Epidemiology, Pathophysiology and Management,&rdquo; <i>Drugs</i>, 2004, 64(6):597-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/15018590/pubmed\" target=\"_blank\" id=\"15018590\">15018590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/28356445/pubmed\" target=\"_blank\" id=\"28356445\">28356445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8641639\"></a>Molica S, Musto P, Chiurazzi F, Specchia G, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. <i>Haematologica</i>. 1996;81(2):121-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/8641639/pubmed\" target=\"_blank\" id=\"8641639\">8641639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morrell A, &ldquo;Pharmacokinetics of Intravenous Immunoglobulin Preparations,&rdquo; <i>Intravenous Immunoglobulins in Clinical Practice</i>, Lee ML and Strand V eds, New York, NY: Marcel Dekker, Inc, 1997, 1-18.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NIH Consensus Conference, &ldquo;Intravenous Immunoglobulin, Prevention and Treatment of Disease,&rdquo; <i>JAMA</i>, 1990, 264(24):3189-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/2255028/pubmed\" target=\"_blank\" id=\"2255028\">2255028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/21325604/pubmed\" target=\"_blank\" id=\"21325604\">21325604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newburger JW, Takahashi M, Gerber MA, et al, &ldquo;Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association,&rdquo; <i>Pediatrics</i>, 2004, 114(6):1708-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/15574639/pubmed\" target=\"_blank\" id=\"15574639\">15574639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NIH Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of disease. <i>JAM</i>A. 1990;264(24):3189-3193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/2255028/pubmed\" target=\"_blank\" id=\"2255028\">2255028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Octagam 5% (immune globulin intravenous [human]) [prescribing information]. Hoboken, NJ: Octapharma USA; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Octagam 10% (immune globulin intravenous [human]) [prescribing information]. Hoboken, NJ: Octapharma USA; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Octagam 10% (immune globulin intravenous [human]) [product monograph]. Toronto, Canada: Octapharma Canada Inc; October 20, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orange JS, Hossny EM, Weiler CR, et al, &ldquo;Use of Intravenous Immunoglobulin in Human Disease: A Review of Evidence by Members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology,&rdquo; <i>J Allergy Clin Immunol</i>, 2006, 117(4 Suppl):525-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/16580469/pubmed\" target=\"_blank\" id=\"16580469\">16580469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Panzyga (immune globulin intravenous [human]) [Canadian product monograph]. Lingolsheim, France and Vienna, Austria: Octapharma; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patwa HS, Chaudhry V, Katzberg H, et al, &ldquo;Evidence-Based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromuscular Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology,&rdquo; <i>Neurology</i>, 2012, 78(13):1009-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/22454268/pubmed\" target=\"_blank\" id=\"22454268\">22454268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Privigen (immune globulin intravenous [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Privigen (immune globulin intravenous [human]) [product monograph]. Ottawa, Ontario, Canada: CSL Behring Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siegel J, &ldquo;Immunoglobulins and Obesity,&rdquo; <i>Pharmacy Practice News</i>, 2010, 37:1.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skeie GO, Apostolski S, Evoli A, et al. European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. <i>Eur J Neurol</i>. 2010;17(7):893-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/20402760/pubmed\" target=\"_blank\" id=\"20402760\">20402760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skvaril F and Gardi A, &ldquo;Differences Among Available Immunoglobulin Preparations for Intravenous Use,&rdquo; <i>Pediatr Infect Dis J</i>, 1988, 7:543-48.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19747629\"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi: 10.1016/j.bbmt.2009.06.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations Consensus Statement,&rdquo; <i>JAMA</i>, 1995, 273(23):1865-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/7776504/pubmed\" target=\"_blank\" id=\"7776504\">7776504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Schaik IN, Winer JB, de Haan R, et al, &ldquo;Intravenous Immunoglobulin for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review,&rdquo; <i>Lancet Neurol</i>, 2002, 1(8):491-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/12849334/pubmed\" target=\"_blank\" id=\"12849334\">12849334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. <i>Neurology</i>. 2007;68(11):837-841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information/abstract-text/17353471/pubmed\" target=\"_blank\" id=\"17353471\">17353471</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16471 Version 208.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F11513229\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F11513233\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11513234\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F11513238\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F11513277\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F11513276\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F11513278\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F11513279\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15897621\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20330560\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F11513299\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F11513236\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F26116456\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49444101\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11513282\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F11513241\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F26122978\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F11513231\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11513249\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11513246\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11513247\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299513\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11513254\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F11513243\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11513244\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20627743\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F11513281\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11513287\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11513265\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11513267\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322887\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059490\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16471|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-patient-drug-information\" class=\"drug drug_patient\">Immune globulin (Intravenous, subcutaneous, and intramsucular): Patient drug information \t</a></li><li><a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">Immune globulin (Intravenous, subcutaneous, and intramsucular): Pediatric drug information</a></li></ul></div></div>","javascript":null}